These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 575490)

  • 1. Acute clinical tolerance of creatinol O-phosphate.
    Melloni GF; Minoja GM; Lureti GF; Merlo L; Pamparana F; Brusoni B
    Arzneimittelforschung; 1979; 29(9a):1447-9. PubMed ID: 575490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects.
    Botti G; Bonatti V
    Arzneimittelforschung; 1979; 29(9a):1491-4. PubMed ID: 575499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and toxicological properties of creatinol O-phosphate. A review.
    Marzo A; Ghirardi P
    Arzneimittelforschung; 1979; 29(9a):1449-52. PubMed ID: 395957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of creatinol O-phosphate (COP) on ventricular fibrillation and death induced by intravenous CaCl2 in mice.
    Ferrini R; Miragoli G
    Arzneimittelforschung; 1979; 29(9a):1473-4. PubMed ID: 575496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of creatinol O-phosphate on serum enzymes in acute myocardial infarction.
    Knippel M; Bana G; Pusterla GL
    Arzneimittelforschung; 1979; 29(9a):1480-2. PubMed ID: 575498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial.
    Di Maio F; Neri A; Soccorsi P; Sciacca A
    Arzneimittelforschung; 1979; 29(9a):1488-90. PubMed ID: 395959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The action of creatinol 0-phosphate on the inotropic effect of isoprenaline in isolated rat atria and in anesthetized dogs.
    Godfraind T; Ghysel-Burton J; Merlo L
    Arzneimittelforschung; 1979; 29(9a):1465-7. PubMed ID: 575493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic effectiveness of creatinol O-phosphate in man.
    Cadel A; Palumbo A; Zerilli G; Pria R; Fanciulli R; Conversano S; Galbiati R
    Arzneimittelforschung; 1979; 29(9a):1485-7. PubMed ID: 94266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creatinol O-phosphate therapy in patients with inadequate coronary circulation. Double-blind clinical trial.
    Barlattani M; Guglielmi G; Mammarella A
    Arzneimittelforschung; 1979; 29(9a):1483-5. PubMed ID: 395958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of creatinol O-phosphate (COP) on some experimental arrhythmias in vitro and in vivo.
    Ferrini R; Miragoli G
    Arzneimittelforschung; 1979; 29(9a):1475-7. PubMed ID: 575497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective action of creatinol O-phosphate against serum CPK activity enhanced by isoprenaline in the rat.
    Marzo A; Ghirardi P
    Arzneimittelforschung; 1979; 29(9a):1471-3. PubMed ID: 575495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creatinol O-phosphate (COP) and muscular performance: a controlled clinical trial.
    Nicaise J
    Curr Ther Res Clin Exp; 1975 Jun; 17(6):531-4. PubMed ID: 808375
    [No Abstract]   [Full Text] [Related]  

  • 13. Action of creatinol-O-phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart.
    Godfraind T; Saleh MM
    Arzneimittelforschung; 1984; 34(9):968-72. PubMed ID: 6542374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of the reduction by creatinol O-phosphate of the myocardial lesions evoked by isoprenaline in the rat.
    Godfraind T; Sturbois X
    Arzneimittelforschung; 1979; 29(9a):1457-64. PubMed ID: 575492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of creatinol-O-phosphate (COP) on haemodynamics and cardiac metabolism in conscious and anaesthetized dogs.
    Marchetti G; Merlo L
    Arzneimittelforschung; 1978; 28(10):1708-11. PubMed ID: 582673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and chemical properties of N- and O-phosphorylated derivatives of creatinol.
    Ferrari G; Casagrande C
    Arzneimittelforschung; 1979; 29(9a):1446-9. PubMed ID: 575489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionic changes evoked by isoprenaline in rat hearts in vivo and in vitro and their reduction by creatinol O-phosphate.
    Godfraind T; Ghysel-Burton J; Sturbois X
    Arzneimittelforschung; 1979; 29(9a):1468-70. PubMed ID: 575494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of creatinol O-phosphate on the isolated rabbit's atrium and on the rat's phrenic nerve diaphragm preparation].
    Ferrini R; Miragoli G
    Farmaco Sci; 1975 Nov; 30(11):912-6. PubMed ID: 1238289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
    De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
    Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.